ArticleBMJ open2024

Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial.

Vincent C J van de Vlasakker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.